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Background. Patients with ulcerative colitis have an increased risk of developing colorectal cancer (CRC). The aim of this study is
to assess the yield of surveillance colonoscopies in a tertiary referral cohort of ulcerative colitis patients and to identify different
risk groups for dysplasia. Methods. A cohort of 293 patients (148 males, mean age 33.8 years at diagnosis) was built up at our
center and started the surveillance program 8–12 years after start of symptoms. They underwent colonoscopies every one to three
years. Endpoints were dysplasia or a (sub)total colectomy. Results. After a follow-up period of 10 years, the cumulative incidence
of any dysplasia was 23.5%, and of CRC 4.0%. After 15 years these percentages were 33.3% and 6.8%. Patients with pancolitis (𝑛 =
178) had a significantly higher cumulative risk of dysplasia than patients with distal disease, HR 1.9 (95%CI 1.1–3.3). Patients who
started surveillance at an older age are at increased risk for any dysplasia, HR 1.03 (95%CI 1.01–1.05). Conclusions. This prospective
surveillance study shows a high yield of dysplasia in ulcerative colitis patients. We recommend developing separate surveillance
programs for different risk groups. In our opinion patients with distal colitis can follow the general population surveillance program.
1. Introduction
Patients with inflammatory bowel disease (IBD) with colon
involvement (both Crohn’s disease (CD) and ulcerative colitis
(UC)) have a 2.4-fold increased overall colorectal cancer
(CRC) risk [1]. CRC accounts for 10–15% of all deaths in
IBD patients, and IBD-related CRC accounts for 1-2% of all
CRC cases in the general population [2, 3]. There is general
agreement that the risk of developing CRC is associated with
the extent of disease in the colon and duration of disease.
Whether young age at onset of disease is an independent risk
factor is controversial [4, 5].
In IBD patients with inflammation in at least 30% of
the colon, colonoscopic surveillance is recommended [6–
9]. Although the effectiveness is limited, it is the best tool
available to detect neoplasia at a curative stage and thus lead
to a better prognosis [8, 10].
A meta-analysis based on a selection of 19UC studies
performed between 1961 and 1995 reports a cumulative
incidences of CRC of 1.6%, 8.3%, and 18.4% after, respectively,
10, 20, and 30 years of disease [4]. In more recent studies, the
cumulative incidences were 0%, 2.5%, and 7.6% in a cohort
with 600UC patients [9] and 1.0%, 2.4%, and 4.8% in a
follow-up study during 24 years in 4125UC patients [11]. A
meta-analysis from Jess et al., including 8 studies from 1995 to
2009, showed overall cumulative colorectal cancer incidence
of <1.0% after 10 years and 1.1%–5.3% after 20 years of follow-
up [1].
The decrease in CRC risk seen in more recent studies
could be explained by more effective treatment or better
colonoscopy techniques to detect abnormalities and enabling
endoscopic and surgical intervention before cancer develops
[9, 12].
Despite a decrease in UC-associated CRC over time, the
diagnosis of CRC is delayed or missed in about 20% of IBD
patients even when monitored according to guidelines [6].
Clearly, current UC surveillance practice leaves considerable
room for improvement in detecting CRC in an early and
curable stage.
The aim of this study is to study the yield of surveillance
of the colon in a tertiary referral cohort of UC patients in
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the period 1980–2012 and to identify high risk groups for
dysplasia.
2. Methods
In a prospective follow-up study, a cohort of 293UC patients
was built up at our center between 1980 and 2005. All patients
were 18 years and older at first surveillance colonoscopy and
the diagnosis of UC was endoscopically and histologically
confirmed. All patients had an intact colon eight years after
the onset of symptoms. The location of the disease was reg-
istered according to the Montreal classification [13]. Patients
with proctitis were not included. The date of the first surveil-
lance colonoscopy (between 1980 and 2005) served as the
entry point of the study. Patients were offered colonoscopies
every three years in the second decade of disease, biannually
in the third decade, and annually from the fourth decade
onwards. Patients with primary sclerosing cholangitis (PSC)
were offered annual colonoscopies starting at the time of PSC
diagnosis. During surveillance, colonoscopies 4 at random
biopsies were taken every 10 cm from coecum to rectum.
Extra biopsies were taken if there were local abnormalities
and polyps [14]. The follow-up time was till April 1, 2012.
Endpoints were dysplasia, loss to follow-up, or a (sub)total
colectomy.
The database of the patients included information about
sex, age at onset of symptoms, age at diagnosis of UC, age
at first surveillance colonoscopy, extent of colitis (distal or
pancolitis), dates and findings of the colonoscopies, histol-
ogy of the colonic biopsies, location and type of dysplasia
and stage of cancer [15], surgery, and date of last surveil-
lance endoscopy. The most severe dysplasia found at each
colonoscopy was recorded in the database.
For classification of the degree of dysplasia the criteria
of Riddell were used (negative for dysplasia, indefinite for
dysplasia, low-grade dysplasia, high-grade dysplasia, and
invasive cancer) [16].
Statistical Analysis.All statistical analyseswere performed
with SPSS version 17.0. The Kaplan-Meyer survival analysis
was used to estimate the follow-up time to event (LGD,HGD,
and CRC). Date of last colonoscopy and (sub)total colectomy
were censoring events.TheCox regressionmodel was used to
predict the influence of different variables on the outcome of
surveillance colonoscopies.
3. Results
3.1. Patient Demographics. A cohort of 293 patients (148
males) was built up at our center. The characteristics of
the study cohort are shown in Table 1. Sixty-one percent
(178 patients) had pancolitis. In 15 patients (5.1%), PSC
was diagnosed. At first surveillance, colonoscopy LGD was
diagnosed in 9 patients (3.1%) and none of the patients had
HGD or CRC. Dysplasia of any grade was detected in 72
patients (24.6%) during the study period which encompassed
2639 person years of follow-up.
Table 1: Characteristics of the patient population (𝑛 = 293).
Mean (sd) Range
years Min. Max.
Age at diagnosis 33.8 (13.8) 4.1 69.4
Age at first surveillance colonoscopy 44.1 (13.8) 18.2 79.3
Age at end of follow-up 53.1 (14.8) 21.2 84.0
Time from onset of symptoms to first
surveillance colonoscopy 12.0 (4.7) 8.0 38.0
Follow-up period of intact colon∗ 10.8 (6.9) 0.1 27.1
Interval between surveillance
colonoscopies∗ 2.0 (1.2) 0.1 10.1
Age at death (𝑛 = 39) 68.1 (16.3) 26.3 97.6
∗Only patients with follow-up colonoscopies, 𝑛 = 245.
A total of 245 patients underwent 1115 surveillance
colonoscopies (mean follow-up period 10.8 (sd. 6.9) years).
The mean age at last colonoscopy was 53.1 (sd. 14.8) years;
46 patients were older than 70 years. Dysplasia of any grade
was detected in 8.3% (92/1115) of the follow-up colonoscopies;
LGD in 6.6% (𝑛 = 74), HGD in 0.5% (𝑛 = 6), andCRC in 1.1%
(𝑛 = 12).
39 patients died during follow-up at a mean age of 68.1
years. The causes of death were CRC (𝑛 = 6), other cancers
(𝑛 = 7), cardiovascular disease (𝑛 = 7), and other causes (𝑛 =
19).
After a follow-up period of 10 years, the cumulative
incidence of patients with any dysplasia was 23.5%, for HGD
6.6% and for CRC 4.0%. After 15 years these percentages were
33.3%, 12.1%, and 6.8%, respectively (Figures 1(a)–1(c)). In
patients with pancolitis the cumulative risk for developing
any dysplasia was 15.0% after 5 years, 28.5% after 10 years,
and 38.6% after 15 years. For patients with distal colitis these
cumulative risks are 11.9%, 13.4%, and 22.5% (Log rank 5.6,
𝑃 = 0.016). The cumulative risk for developing HGD in
patients with pancolitis was 5.6% after 5 years, 9.6% after 10
years, and 18.1% after 15 years. For patients with distal colitis
this risk was 1.1% after 15 years (just one patient) (Log rank
10.8, 𝑃 = 0.001).
Table 2 shows the number of patients with dysplasia
adjusted for sex, extent of disease, and age at first surveil-
lance colonoscopy by the Cox proportional hazard model,
univariate, and multivariate analysis.There was no difference
in detection rate of dysplasia between males and females.
Patients with pancolitis had a significantly higher cumulative
risk of developing any dysplasia in comparison with patients
with distal UC (HR 1.89, 𝑃 = 0.002). For HGD/CRC, the
hazard ratio was 13.51 (𝑃 = 0.01). The age at first surveillance
colonoscopy had a significant contribution in the prediction
of any dysplasia. Patients receiving their first surveillance
colonoscopy at an older age are at increased risk for any
dysplasia of the colon, independent of disease duration, HR
1.03 (𝑃 = 0.007). For HGD and CRC, this increased risk
at older age was not seen. In this cohort, the starting point
of surveillance in years from onset of symptoms was not a
significant predictor of detection of any dysplasia during the
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Figure 1: (a) Cumulative risk of any dysplasia. (b) Cumulative risk of HGD and CRC. (c) Cumulative risk of CRC.
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follow-up period (HR 1.01, 𝑃 = 0.78) nor for CRC (HR 1.03,
𝑃 = 0.58).
3.2. Carcinogenesis. Low-grade dysplasia was detected in 83
colonoscopies in 55 patients.The next colonoscopy after LGD
detection was 27 times within one year and 31 times after
1 year (max. 5.1 years). In 25 cases, no next colonoscopy
was done because of loss to follow-up or comorbidity, or a
surgical resection procedure (8 cases). Ten patients, 18.2%
(10/55), showed progression of LGD to HGD and/or CRC. In
eight colonoscopies (7 patients), progression of LGD toHGD
and/or CRC was seen in less than 2 years and 3 months after
LGD detection. In two other patients, HGD was detected in
the resection specimen. In the tenth patient, CRC was found
by CT scan 15.2 years after the last surveillance colonoscopy
and 16.1 years after LGD detection.
Concerning the HGD/CRC patients, LGD preceded
HGD/CRC in 10 of 23 (43.5%) patients. No significant
differences in patient characteristics were seen between the
patients with and without LGD prior to HGD and/or CRC.
3.2.1. Colorectal Cancer. During the follow-up period, one
patient was diagnosed with a neuroendocrine colon tumor
and one patient with a colon localization of a B-cell lym-
phoma. A total of 15 patients (5.1%) were diagnosed with
colorectal adenocarcinoma (14/178 patients with pancolitis;
7.9%) during the follow-up period at a mean age of 49.2
years (range 24.9–65.6 years). Two patients were known with
PSC.The shortest interval from onset of symptoms of UC till
CRC diagnosis was 10.2 years. The mean interval from last
surveillance colonoscopy until CRC diagnosis was 2.4 (sd.
3.8) years.
Twelve CRCs were detected during a surveillance colon-
oscopy. One cancer was diagnosed in a resection specimen;
two were detected by a CT scan performed because of
abdominal complaints. Three tumors were located in the
rectum, six were distal colon tumors, and six were found
in the right side of the colon. Eight patients were at stage I
(𝑛 = 3) and stage II (𝑛 = 5). Stage III was diagnosed in four
patients and stage IV in three patients. In 7 patients, CRCwas
not preceded by surveillance-detected dysplasia. Eight of the
15 CRC patients died, fromwhich 6 due to CRC at amean age
of 49.0 (sd. 14.5) years.
3.2.2. Resection Specimens. Patients who underwent colorec-
tal surgery were censored at the date of last surveillance
colonoscopy before surgery. Results from last surveillance
colonoscopy and resection specimen were compared. A total
of 61 patients underwent a surgical resection procedure, 36
patients because of therapy resistant UC and 25 patients
because of any degree of dysplasia. In 50 patients the resection
specimen confirmed the outcome of the colonoscopy (includ-
ing biopsies) performed before the surgery. In 8 patients, the
resection specimen showed a higher degree of dysplasia than
had been diagnosed at colonoscopy; in 3 patients the degree
of dysplasia detected in the surgical specimen was lower than
had been reported by the pathologist based on the biopsies
taken at colonoscopy.
4. Discussion
This large prospective surveillance study in a tertiary referral
center among patients with UC shows a low yield of dysplasia
at the first life-time surveillance colonoscopy. During follow-
up endoscopies, the yield is significant. No difference in sex
was observed. Patients with extensive disease have a higher
risk of developing dysplasia/CRC. Patients who have their
first surveillance colonoscopy at older age are at increased risk
for any dysplasia of the colon, independent of disease years.
Nearly half of the patients with HGD/CRC were diagnosed
with LGD before.
We found any dysplasia in 72 of 293UC patients (24.6%).
The same proportion, 25%, was found in 2005 by Lindberg
et al. [17]. This study shows an overall CRC incidence of
5.1% in contrast to other studies with incidences of 1.6–3.7%
[1, 4, 11]. We detected a cumulative incidence of any dysplasia
of 23.5% by 10 years and 48.3% by 20 years and of CRC these
incidences were 4.0% after 10 years and 14.2% after 20 years.
Our dysplasia cumulative incidence is quite higher than in
most series, with cumulative incidences of 1.5–10.0% for any
dysplasia and 0%–8% for CRC [4, 9, 18]. These differences
have several possible explanations.
Themajority (61%) of the study population hadpancolitis,
with an increased risk for any dysplasia compared to the
patients with distal colitis, HR 1.9 (𝑃 = 0.02). Patients
with pancolitis had a significantly higher incidence of CRC
than patients with distal colitis, HR 8.4 (𝑃 = 0.04). On the
other hand, even in patients with pancolitis the incidence of
CRC is higher in our cohort compared with previous cohorts
(7.9% in this study versus 5.4%) [4, 11]. Another reason
for the relatively high incidence of dysplasia in our cohort
could be the method of analysis. In previous studies, patients
with colectomy remain in the analysed study population,
which decreases the yield of the surveillance [4, 6]. Lack of
mucosal healing in a substantial proportion of our cohort is
probably the major reason for the high incidences of CRC
and any dysplasia. Analyzing the fifteen CRC patients, they
were not in clinical remission before CRC diagnosis. Despite
medication use, chronic active (multi)focal disease and scar
tissue were seen at endoscopy and/or in biopsies. The LUMC
is a tertiary referral center where mainly severe cases are
treated.
In a meta-analysis of Jess et al. a gender-related risk was
found, in favor of females, probably related to a protective
effect of estrogens in women [1].We found slightlymore CRC
in women than in men in this study, though not significant,
HR 0.75 (𝑃 = 0.6).
Themean age at diagnosis of UC in our cohort is the same
as the patient populations in previous studies [6, 19, 20]. The
median age at CRC diagnosis was 49.9 years (range 24–71)
and this is comparable to results from other studies (49.0–
55.5 years) [6, 9, 21]. In a study from 2008, the left colon
was themain location for CRCs; our study corroborates these
findings with 60% of CRCs (9/15) located in the left colon [6].
In a meta-analysis from 2001, a slight increase in the
incidence of CRC over time was found, explained by an
increased CRC detection by surveillance programs [4].
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Table 2: Cox regression analysis per independent factor.
(a) Positive for any dysplasia
Factors Number (%) Univariate Multivariate
HR 95% CI Sig. HR 95% CI Sig.
Sex 1,552 0.963–2.502 0.071 1,430 0.878–2.329 0.150
Male 45/148 (30.4)
Female 27/145 (18.6)
Location 1,922 1.115–3.312 0.019 1,918 1.111–3.311 0.019
Pancolitis 55/178 (30.9)
Distal colitis 17/115 (14.8)
Age at 1st surveillance, yrs 1,032 1.013–1.051 0.001 1,028 1.009–1.047 0.004
(b) Positive for HGD/CRC
Factors Number (%) Univariate Multivariate
HR 95% CI Sig. HR 95% CI Sig.
Sex 1,354 0.586–3.129 0.479 1,460 0.624–3.421 0.383
Male 14/148 (9.5)
Female 9/145 (6.2)
Location 13,232 1.783–98.182 0.012 13,508 1.818–100.384 0.011
Pancolitis 22/178 (12.4)
Distal colitis 1/115 (0.9)
Age at 1st surveillance, yrs 1,008 0.975–1.042 0.654 1,002 0.968–1.036 0.926
(c) Positive for CRC
Factors Number (%) Univariate Multivariate
HR 95% CI Sig. HR 95% CI Sig.
Sex 0.748 0.271–2.064 0.575 0.874 0.310–2.460 0.798
Male 7/148 (4.7)
Female 8/145 (5.5)
Location 8,305 1.092–63.165 0.041 8,402 1.102–64.062 0.040
Pancolitis 14/178 (7.9)
Distal colitis 1/115 (0.9)
Age at 1st surveillance, yrs 0.986 0.943–1.031 0.531 0.984 0.941–1.029 0.486
This is in contrast to the study of Rutter et al. Their results
showed a significant reduction in the incidence of CRC over
time [9].
The benefit of a surveillance program for patients at
increased risk for CRC is not clear from our study. On the
one hand, twelve of fifteen (80.0%) patients were diagnosed
with CRC at surveillance colonoscopy, which is comparable
with previous studies [22]. On the other hand, we found a
higher proportion CRCs in stage IV and a lower proportion
in stage I at diagnosis in comparison with other studies
[22, 23], with proportionsmore similar to the nonsurveillance
population of the study of Lutgens, though we cannot make
any conclusion about it because of the small absolute number
of CRCs in our cohort [22].
Although the interval between onset of symptoms of
UC and first surveillance colonoscopy was not a significant
predictor for detection of dysplasia in our study, the earliest
cancer 10.2 years, after onset of symptoms, provides further
support for starting surveillance 10 years after the onset
of symptoms.Despite the high yield of dysplasia of the
surveillance program in our study, 20% of CRCs presented
as interval cancers between surveillance examinations. Gas-
troenterologists may overlook dysplasia of the mucosa of the
colon and it is important to realise that dysplasia and cancer
can still arise despite adherence to a surveillance program
[17, 24].
The reported progression rates of LGD to HGD and CRC
have a wide range from 7.1% of 28 LGD patients to 39.1% of
46 LGD patients [21, 25]. In our cohort, this rate was 18.2%
of 55 patients. In 70% (7/10) of these patients, LGD showed
progression in less than two years and three months. This
finding would support the current practice of decreasing the
interval to the next colonoscopy after LGD detection [14, 26].
Mortality due to CRC has decreased gradually over the
last decades [2, 17, 27, 28]. Our patients entered the study in
the period 1980–2005. The surveillance strategies were not
changed during this period. In 2010, the IBD surveillance
program of the LUMC was changed in line with the revised
recommendations of the British Society of Gastroenterology
for colorectal cancer screening in IBD patients published in
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2010 [12, 26]. In the current study, we did not use adjunctive
colonoscopy techniques like chromoscopy andNBI. Probably
these techniques will further increase the detection rate of
dysplasia and decrease the incidence of colorectal cancer.
In summary, this study provides further evidence that
patients with pancolitis should enter a surveillance program
10 years after the start of symptoms [12]. This study suggests
that patients with left-sided colitis have a similar CRC risk
as the general population and do not need a more intense
surveillance schedule.This study confirms that a surveillance
program is capable of detecting the great majority of CRCs
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